Payment overview · 2025
General Payments
$196.80
9 reported records · 4 companies
Healthcare provider profile · identity verified
Brian N Carter, MD
Allopathic & Osteopathic Physicians|Internal Medicine · GRANGER, IN · NPI 1366432429
Verified facts
What the public records show
CMS Open Payments records show Brian N Carter, MD received $196.80 in general payments during 2025 across 9 reported records.
ABBVIE INC. accounted for 49.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $98.04 | 49.8% | 4 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $43.44 | 22.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $36.47 | 18.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.85 | 9.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $177.95 | 8 |
| Education | $18.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $81.89 | 3 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $43.44 | 2 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $22.10 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
50 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 656 | 191 |
| Levothyroxine Sodium | Levothyroxine Sodium | 323 | 86 |
| Lisinopril | Lisinopril | 293 | 86 |
| Amlodipine Besylate | Amlodipine Besylate | 289 | 83 |
| Metoprolol Succinate | Metoprolol Succinate | 188 | 57 |
| Losartan Potassium | Losartan Potassium | 181 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 176 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 153 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 151 | 45 |
| Omeprazole | Omeprazole | 121 | 35 |
| Metformin Hcl Er | Metformin Hcl | 120 | 35 |
| Tramadol Hcl | Tramadol Hcl | 120 | 26 |
| Metformin Hcl | Metformin Hcl | 119 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 107 | 34 |
| Trazodone Hcl | Trazodone Hcl | 106 | 31 |
| Glipizide | Glipizide | 98 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 95 | 27 |
| Gabapentin | Gabapentin | 95 | 31 |
| Allopurinol | Allopurinol | 92 | 27 |
| Furosemide | Furosemide | 86 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 80 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 78 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 76 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 73 | 28 |
| Eliquis | Apixaban | 72 | 19 |
| Alprazolam | Alprazolam | 67 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | 19 |
| Prednisone | Prednisone | 54 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 53 | 20 |
| Meloxicam | Meloxicam | 51 | 19 |
| Synthroid | Levothyroxine Sodium | 50 | 13 |
| Sertraline Hcl | Sertraline Hcl | 48 | 12 |
| Simvastatin | Simvastatin | 48 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | 14 |
| Januvia | Sitagliptin Phosphate | 45 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 45 | 13 |
| Pregabalin | Pregabalin | 45 | 11 |
| Atenolol | Atenolol | 43 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | 13 |
| Bupropion Xl | Bupropion Hcl | 42 | 11 |
| Potassium Chloride | Potassium Chloride | 41 | 13 |
| Famotidine | Famotidine | 39 | 12 |
| Glipizide Er | Glipizide | 39 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 39 | 11 |
| Finasteride | Finasteride | 37 | 11 |
| Ozempic | Semaglutide | 36 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 11 |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 33 | suppressed |
| Lovastatin | Lovastatin | 33 | suppressed |
| Celecoxib | Celecoxib | 32 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 31 | 11 |
| Spironolactone | Spironolactone | 31 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 30 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | 12 |
| Trulicity | Dulaglutide | 29 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 28 | 28 |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Cephalexin | Cephalexin | 27 | 22 |
| Clonazepam | Clonazepam | 27 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 27 | suppressed |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Carvedilol | Carvedilol | 25 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Acyclovir | Acyclovir | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 21 | 21 |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 17 |
| Diazepam | Diazepam | 19 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 17 |
| Glimepiride | Glimepiride | 18 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 18 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | 11 |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 13 |
| Bethanechol Chloride | Bethanechol Chloride | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 13 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $196.80 · 9 records | ABBVIE INC. | INSPIRE, JARDIANCE, PENMENVY, SHINGRIX, UBRELVY, VRAYLAR | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error